University of Arizona HHSN261201200031I;Task Order

亚利桑那大学 HHSN261201200031I；任务顺序

• 批准号: 8947593
• 负责人: SHERRY CHOW
• 金额: $ 15.16万
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-15 至 2014-10-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8947593
• 关键词: Arizona; Biological Markers; California; Chemoprevention; Clinical; Clinical Trials; Colorectal Cancer; Contractor; Data; Data Reporting; Development; Division of Cancer Prevention; Drug Industry; Funding; Individual; Malignant Neoplasms; Malignant neoplasm of liver; Manuscripts; Metformin; Methionine; Monitor; National Cancer Institute; Performance; Phase; Prevention program; Preventive; Reporting; Resources; Site; Universities; Visit; Work; cancer prevention; colorectal cancer prevention; data management; interest; prevention clinical trial; programs

The National Cancer Institute (NCI), Division of Cancer Prevention (DCP) Phase 0/I/II Cancer Prevention Clinical Trials Program supports early clinical trials to rapidly evaluate the clinical activity and biologic effects of cancer preventive agents of interest to DCP. The agents to be studied shall include agents developed by the pharmaceutical industry and provided to DCP for collaborative development, commercially available agents, and agents developed by DCP. The University of California at Irvine (UC Irvine) has finished accrual to multiple chemoprevention studies funded by the DCP Program, but requires additional resources to perform biomarker analyses, site monitoring, data management and closure, final report development/submission, and final data reporting to Clinicaltrials.gov. UC Irvine is the only organization capable of performing these tasks since the clinical trials were performed by UC Irvine.

美国国家癌症研究所（NCI）癌症预防部（DCP）0/I/II期癌症预防临床试验计划支持早期临床试验，以快速评估DCP感兴趣的癌症预防剂的临床活性和生物学效应。待研究的制剂应包括由制药行业开发并提供给DCP进行合作开发的制剂、市售制剂和DCP开发的制剂。加州尔湾大学（UC Irvine）已完成DCP项目资助的多项化学预防研究的应计费用，但需要额外资源进行生物标志物分析、研究中心监查、数据管理和关闭、最终报告编制/提交以及向Clinicaltrials. gov报告最终数据。UC Irvine是唯一能够执行这些任务的组织，因为临床试验由UC Irvine进行。